<scp>Real‑world</scp> survival outcome comparing abiraterone acetate plus prednisone and enzalutamide for <scp>nonmetastatic castration‐resistant</scp> prostate cancer

Takuya Tsujino(Osaka University of Pharmaceutical Sciences), Haruhito Azuma(Osaka University of Pharmaceutical Sciences), Yosuke Hirasawa(Cedars-Sinai Medical Center), Atsuhiko Yoshizawa(Fujita Health University Hospital), Fumihiko Urabe(Jikei University School of Medicine), Kosuke Iwatani(Jikei University School of Medicine), Shogo Yamazaki(Osaka University of Pharmaceutical Sciences), Ryoichi Maenosono(Osaka University of Pharmaceutical Sciences), Wataru Fukuokaya(Jikei University School of Medicine), Keita Nakamori(Osaka University of Pharmaceutical Sciences), Keiichiro Mori(Jikei University School of Medicine), Kazuki Nishimura(Osaka University of Pharmaceutical Sciences), Takafumi Yanagisawa(Jikei University School of Medicine), Takahiro Adachi(Tokyo Medical University), Shutaro Yamamoto, Masanobu Saruta(Fujita Health University), Shunsuke Tsuzuki(Jikei University School of Medicine), Yoshio Ohno(Tokyo Medical University), Teruo Inamoto(Hamamatsu University), Takeshi Hashimoto(Tokyo Medical University), Kazumasa Komura(Kawasaki Medical School), Ryoichi Shiroki(Fujita Health University), Satoshi Tokushige(Osaka University of Pharmaceutical Sciences), Takahiro Kimura(Jikei University School of Medicine), Takaya Ohno(Osaka University of Pharmaceutical Sciences), Taizo Uchimoto(Osaka University of Pharmaceutical Sciences), Kiyoshi Takahara(Osaka Medical and Pharmaceutical University)
Cancer Medicine
September 14, 2023
Cited by 4


Related Papers